The results showed high killing potential in ovarian cancer cell lines and a significant tumor growth inhibition in animals, indicating that the DTA-H19 construct has a high therapeutic potential and is a very promising candidate for ovarian cancer therapy in humans. The gene discussed is H19; the disease is ovarian carcinoma.